Zydus Cadila and Eczacibasi, a Turkish Healthcare Company have signed a strategic collaboration agreement to market biotech products in the Turkish market. The agreement involves the import of biosimilars which are currently unavailable in the country especially for the treatment of cancer and also paves the way for a long term strategic collaboration to produce and launch new products in the market.
Why Biosimilar has different approval process than generic drugs? >> View
First Biosimilar in US market >> View
Learn recent developments related to Biosimilar drugs >> View